Kymera Therapeutics Presents Preclinical Data Demonstrating Activity of KT-253, a Selective Heterobifunctional MDM2 Degrader, in Acute Myeloid Leukemia at the American Society of Hematology Annual Meeting

Author's Avatar
Dec 11, 2022

A single dose of KT-253 induced rapid apoptosis and sustained tumor regression in xenograft models of AML